Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020
Effects of pretreatment prognostic factors and treatment on survival in advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003
Hypoxia-response gene signatures as predictive and prognostic biomarkers in advanced non-squamous non-small cell lung cancer patients Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015
Bcl-2 as a prognostic factor for survival in small-cell lung cancer Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
PD-L1 is a potential negative prognostic factor for non-small cell lung cancer: A 5-year-follow-up study Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
Prognostic factors affecting survival in advanced non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004
Effects of prognostic factors on survival of the patients of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 326s Year: 2005
Assessing the relevance of biological prognostic indices in predicting survival in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Evaluation of the role of EGFR as prognostic factor in stage III non-small cell lung cancer (NSCLC): a retrospective analysis Source: Eur Respir J 2004; 24: Suppl. 48, 478s Year: 2004
Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK -rearranged non-small cell lung cancer Source: Eur Respir J, 51 (5) 1702431; 10.1183/13993003.02431-2017 Year: 2018
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007
TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Is gender a prognostic factor in long term survival non-small cell lung cancer? Source: Eur Respir J 2002; 20: Suppl. 38, 185s Year: 2002
Nuclear and microenvironment interactions could be useful biological prognostic markers for adjuvant therapy in advanced non-small cell lung carcinoma Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002
HER2/Neu overexpression as independent negative prognostic factor for non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy Source: Eur Respir Rev 2013; 22: 565-576 Year: 2013
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011
Is neutrophil/lymphocyte ratio at the time of diagnosis a valuable prognostic factor in non-small cell lung cancer? Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018